1. Home
  2. CLB vs LBRX Comparison

CLB vs LBRX Comparison

Compare CLB & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

HOLD

Current Price

$11.77

Market Cap

864.2M

Sector

N/A

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$29.48

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLB
LBRX
Founded
1936
2015
Country
United States
United States
Employees
3300
27
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
864.2M
850.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
CLB
LBRX
Price
$11.77
$29.48
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$12.50
$46.60
AVG Volume (30 Days)
526.0K
149.5K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
0.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$526,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.51
N/A
52 Week Low
$9.72
$13.40
52 Week High
$20.36
$33.47

Technical Indicators

Market Signals
Indicator
CLB
LBRX
Relative Strength Index (RSI) 31.42 56.60
Support Level $11.76 $26.44
Resistance Level $13.03 $30.42
Average True Range (ATR) 0.55 1.68
MACD -0.08 0.11
Stochastic Oscillator 2.59 88.15

Price Performance

Historical Comparison
CLB
LBRX

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: